Sharck Soup Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Sharck Soup

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: besttrader who wrote (27635)	6/14/2001 10:03:20 AM
From: Frederick Langford	Read Replies (1) of 37746

I like IVX IVAX Expects Second Quarter Earnings to Exceed Analysts' Expectations and Anticipates Increased Paclitaxel Sales Business Editors MIAMI--(BUSINESS WIRE)--June 13, 2001--IVAX Corporation (AMEX:IVX) expects that its second quarter earnings will exceed analysts' expectations, based on preliminary results from operations for the first two months of the quarter, together with sales made and expected to be made during June. The First Call analyst consensus estimate for IVAX is currently $.25 per share. IVAX plans to announce its second quarter earnings near the end of July. Financial results to date indicate that IVAX will have a strong quarter and sales of IVAX' paclitaxel injection product are expected to be greater than in the first quarter of 2001. IVAX Corporation, headquartered in Miami, Florida, is engaged in the research, development, manufacturing and marketing of branded and brand equivalent pharmaceuticals and veterinary and diagnostic products throughout the world. Fred

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next